Inflammatory Bowel Disease Market Report by DelveInsight

Inflammatory Bowel Disease companies are Takeda, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, AstraZeneca, and others.

LAS VEGAS, NEVADA, UNITED STATES, June 27, 2024 /EINPresswire.com/ -- DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Bowel Disease Market Forecast

Some of the key facts of the Inflammatory Bowel Disease Market Report:
The Inflammatory Bowel Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
Key Inflammatory Bowel Disease Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others
Key Inflammatory Bowel Disease Therapies: Entyvio (Vedolizumab), Stelara (Ustekinumab), Etrolizumab (RG7413), Skyrizi (Risankizumab/BI 655066/ABBV-066), and others
The market size of IBD in the APAC region is expected to reach USD 3,672 million by 2030.
In 2021, China accounted for the highest market size of IBD, compared to the other major markets, i.e., USD 748 million.
Among the other APAC countries apart from China, Japan had the highest market size with USD 709 million in 2021, while South Korea had the lowest market size of IBD with USD 75 million in 2021.
Of the emerging therapies Skyrizi, Etrolizumab, Jyselica and others are expected to enter the treatment market, during the forecast period. Alofisel is recently approved in Japan in 2021 and is expected to enter the other APAC countries.
The expected launch of potential therapies shall increase the market size in the coming years, assisted by an increase in the prevalent population of IBD during the forecast period.
Total prevalent population of IBD in the APAC regions was 3,907,112 cases in 2021 which is expected to increase during the study period.
Japan accounted for third highest (205,859) cases of IBD, compared to other Asian regions (China (1,917,172 cases), India (1,566,102 cases), Australia (168,539 cases), and South Korea (49,440 cases)) in 2021.
Males accounted for a higher number of IBD cases in the APAC region in 2021. There were 1,708,495 cases and 1,293,034 cases of IBD in males and females respectively in 2021.
The maximum number of prevalent IBD cases in the APAC region were found in the age group 40+ years, followed by those aged 20–39 years. As per estimates, the age group of 40+ years contributed to 1,549,013 cases in 2021, which is anticipated to increase throughout the study period 2018─2030.
IBD patients are further classified based on the severity of the disease. Patients with mild, and moderate to severe accounts for approximately 1,014,670 cases, and 1,986,860 cases respectively in 2021.
The Inflammatory Bowel Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.

Inflammatory Bowel Disease Overview
The digestive system, one of the body's largest organ systems, begins at the mouth where food enters and extends to the anus for waste expulsion. Similar to other bodily systems, it can be affected by various conditions, among them inflammatory bowel disease (IBD). IBD encompasses disorders characterized by chronic inflammation of different parts of the digestive tract, including the mouth, esophagus, stomach, small intestine, and large intestine. Its primary functions include breaking down food, absorbing nutrients, and eliminating waste. Inflammation disrupts these functions, leading to difficulties in nutrient absorption. IBD is a chronic or recurring condition consisting of two main types: Crohn’s disease (CD) and Ulcerative colitis (UC), which share similarities while also presenting distinct characteristics.

Inflammatory Bowel Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Inflammatory Bowel Disease Epidemiology Segmentation:
The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Inflammatory Bowel Disease
Prevalent Cases of Inflammatory Bowel Disease by severity
Gender-specific Prevalence of Inflammatory Bowel Disease
Diagnosed Cases of Episodic and Chronic Inflammatory Bowel Disease
Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ Inflammatory Bowel Disease Epidemiology Forecast

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Inflammatory Bowel Disease Therapies
Entyvio (Vedolizumab)
Stelara (Ustekinumab)
Etrolizumab (RG7413)
Skyrizi (Risankizumab/BI 655066/ABBV-066)
Inflammatory Bowel Disease Key Companies
Takeda Pharmaceutical
Janssen Pharmaceuticals
Hoffmann-La Roche
Genentech
AbbVie
Boehringer Ingelheim
Gilead Sciences
Arena Pharmaceuticals
Eli Lilly
AstraZeneca
Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ Inflammatory Bowel Disease Treatment Landscape

Inflammatory Bowel Disease Market Outlook
Inflammatory Bowel Disease (IBD) encompasses gastrointestinal conditions such as ulcerative colitis (UC) and Crohn’s Disease (CD), characterized by a relapsing-remitting course affecting individuals of all ages. Current treatment options for IBD include traditional therapies like aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors, anti-TNF agents, anti-adhesion molecules, as well as newer approaches such as small molecules targeting JAK pathways, anti-IL12/23 therapies, and cell-based treatments.

Various types of immunomodulators with distinct mechanisms of action are utilized in treating IBD patients across the Asia-Pacific (APAC) region. TNF inhibitors have significantly altered the treatment landscape for UC and CD, although their use is limited due to systemic side effects like immunosuppression and cardiotoxicity, particularly in elderly patients, even among responders to TNF therapy. In 2020, Humira (adalimumab) emerged as a leading anti-TNF therapy for managing multiple conditions, including CD and UC. It received approval in Japan for treating Crohn’s Disease (CD) in 2010. Amgevita, a biosimilar of Humira, was approved by the Australian Therapeutic Goods Administration in 2017 for various indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, CD in adults and children (≥6 years), ulcerative colitis, psoriasis in adults and children, hidradenitis suppurativa, and uveitis.

Another anti-TNF therapy, infliximab, was approved by Japanese regulators in 2002 for CD treatment, later extended to UC as well. In 2018, Chinese guidelines included infliximab for UC treatment. Additionally, in 2018, the Australian regulatory authority approved the infliximab biosimilar Inflectra for managing adult and pediatric Crohn’s disease, refractory fistulising CD, and adult and pediatric UC.

Scope of the Inflammatory Bowel Disease Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Inflammatory Bowel Disease Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others
Key Inflammatory Bowel Disease Therapies: Entyvio (Vedolizumab), Stelara (Ustekinumab), Etrolizumab (RG7413), Skyrizi (Risankizumab/BI 655066/ABBV-066), and others
Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies
Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Inflammatory Bowel Disease Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Bowel Disease Market Access and Reimbursement

Table of Contents
1. Inflammatory Bowel Disease Market Report Introduction
2. Executive Summary for Inflammatory Bowel Disease
3. SWOT analysis of Inflammatory Bowel Disease
4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance
5. Inflammatory Bowel Disease Market Overview at a Glance
6. Inflammatory Bowel Disease Disease Background and Overview
7. Inflammatory Bowel Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Inflammatory Bowel Disease
9. Inflammatory Bowel Disease Current Treatment and Medical Practices
10. Inflammatory Bowel Disease Unmet Needs
11. Inflammatory Bowel Disease Emerging Therapies
12. Inflammatory Bowel Disease Market Outlook
13. Country-Wise Inflammatory Bowel Disease Market Analysis (2019–2032)
14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies
15. Inflammatory Bowel Disease Market Drivers
16. Inflammatory Bowel Disease Market Barriers
17. Inflammatory Bowel Disease Appendix
18. Inflammatory Bowel Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Inflammatory Bowel Disease Pipeline
"Inflammatory Bowel Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Inflammatory Bowel Disease market. A detailed picture of the Inflammatory Bowel Disease pipeline landscape is provided, which includes the disease overview and Inflammatory Bowel Disease treatment guidelines.
Inflammatory Bowel Disease Epidemiology
DelveInsight's 'Inflammatory Bowel Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Inflammatory Bowel Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.